By:- B.T Team

Image Credit:- Google

Syngene Q4 Beat

Syngene Surprises: Profit Beat & US Deal! Big profit growth and a major US acquisition—details inside!

Net Profit: ₹183.3 Cr Up 2.8% YoY Beat estimates of ₹177 Cr!

Profit Overview

Revenue: ₹1,018 Cr Up 11% YoY Missed expected ₹1,066 Cr

Revenue Performance

EBITDA Results

EBITDA: ₹343.6 Cr Up 8.4% YoY Slight miss vs expected ₹350 Cr

EBITDA Margin

EBITDA Margin: 33.8% Down from 34.4% YoY Exceeded the projected 33%

Dividend Declaration

Final Dividend: ₹1.25/share Subject to shareholder approval for FY25

Big Acquisition

New Facility in the US! Acquired a biologics manufacturing facility to expand in the CDMO sector.

CEO's Vision

Peter Bains, CEO: “Strong growth in biologics & discovery services. US acquisition positions us for long-term success.”

Stock Market Reaction

Stock Price: ₹754 Up 2.5% on BSE after earnings report

Future Outlook

Focus on: – Biologics Manufacturing – Research & Discovery Services Positioned for long-term growth in FY25 and beyond

Watch More Story

Deloitte Internship 2025